Ma, Qin http://orcid.org/0000-0001-6642-0858
Shams, Hengameh
Didonna, Alessandro
Baranzini, Sergio E. http://orcid.org/0000-0003-0067-194X
Cree, Bruce A. C.
Hauser, Stephen L. http://orcid.org/0000-0002-4932-4001
Henry, Roland G. http://orcid.org/0000-0002-8232-7562
Oksenberg, Jorge R. http://orcid.org/0000-0002-3613-9544
Funding for this research was provided by:
National Multiple Sclerosis Society (RFA-2104-37474, FG-2108-38348, FG-1807-31603)
U.S. Department of Health & Human Services | National Institutes of Health (R35NS111644)
Valhalla Foundation
Article History
Received: 2 November 2022
Accepted: 14 March 2023
First Online: 30 March 2023
Competing interests
: S.L.H. currently serves on the scientific advisory board of Accure, Alector, Annexon, board of directors of Neurona, and has previously consulted for BD, Moderna, and NGM Bio. S.L.H. also has received travel reimbursement and writing support from F. Hoffmann-La Roche and Novartis AG for anti-CD20-theapy-related meetings and presentations. Other authors declare no competing interests.